HC Wainwright Has Optimistic Outlook of Evommune Q2 Earnings

Evommune, Inc. (NYSE:EVMN) – Stock analysts at HC Wainwright increased their Q2 2026 earnings estimates for Evommune in a research report issued on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their previous forecast of ($0.71). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Evommune’s current full-year earnings is ($2.86) per share. HC Wainwright also issued estimates for Evommune’s Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.77) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.33) EPS.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus began coverage on shares of Evommune in a research note on Friday, May 1st. They issued a “buy” rating and a $54.00 price objective for the company. Evercore reissued an “outperform” rating and issued a $55.00 price objective on shares of Evommune in a research note on Tuesday, February 10th. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Oppenheimer began coverage on shares of Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective for the company. Finally, Clear Str raised shares of Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $49.25.

Evommune Trading Up 0.2%

NYSE EVMN opened at $23.39 on Thursday. The company has a 50 day simple moving average of $24.20. Evommune has a one year low of $13.89 and a one year high of $33.20. The stock has a market capitalization of $842.62 million and a price-to-earnings ratio of -2.46.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in EVMN. EQT Fund Management S.a r.l. purchased a new position in Evommune in the fourth quarter worth approximately $84,395,000. RA Capital Management L.P. purchased a new position in Evommune in the fourth quarter worth approximately $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in Evommune in the fourth quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd purchased a new position in Evommune in the fourth quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. purchased a new position in Evommune in the fourth quarter worth approximately $22,408,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.